SCHEMBL304075

SCHEMBL304075

COc1cccc(-n2ncc3c(Br)cc(C)cc32)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.50
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
XBP1 P17861 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
TSHR P16473 2/20 0.46
LMNA P02545 2/20 0.46
CYP17A1 P05093 1/20 0.46
CYP1A2 P05177 1/20 0.46
USP7 Q93009 1/20 0.44
NPBWR1 P48145 2/20 0.43
MCHR1 Q99705 2/20 0.43
SMN1; SMN2 Q16637 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303393 0.86 NPBWR1 (0.50) NR3C1KDM4EALDH1A1MAPTHSD17B10
SCHEMBL4398029 0.86 NPC1 (0.49) NR3C1KDM4EALDH1A1MAPTHSD17B10
SCHEMBL303854 0.83 RAB9A (0.44) NR3C1KDM4EALDH1A1MAPTHSD17B10
SCHEMBL1773970 0.79 NR3C1 (0.45) NR3C1KDM4EALDH1A1MAPTHSD17B10
SCHEMBL9609001 0.77 NR3C1 (0.44) NR3C1MEN1KMT2ANPBWR1MCHR1
SCHEMBL304064 0.75 NR3C1 (0.47) NR3C1ALDH1A1MAPTTSHRLMNA
SCHEMBL30596268 0.74 NPBWR1 (0.48) NR3C1KDM4EALDH1A1MAPTHSD17B10
SCHEMBL17582162 0.73 NPC1 (0.50) NR3C1KDM4EALDH1A1MAPTHSD17B10
SCHEMBL837601 0.73 SMO (0.51) NR3C1ALDH1A1MAPTHPGDNPSR1
SCHEMBL1774427 0.73 TDP1 (0.44) NR3C1KDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869003-B1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LTD (GB) 2013-05-15 EP disclosed
EP-1869003-B1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LTD (GB) 2013-05-15 EP disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-8093281-B2 Indazoles as glucocorticoid receptor ligands GLAXO GROUP LIMITED (GB) 2012-01-10 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090074675-A1 INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS NR3C1, NR3C2, MC2R NR3C1 1/4885KDM4E 2479/4885ALDH1A1 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.